Colon cancer - case study

Tags:

Health • Digestive System

Eps 1: Colon cancer - case study

Colon Cancer

After 2 months on therapy, repeat imaging reveals stable disease.
Patients with RAS-wild-type metastatic colon cancer who have been previously treated with oxaliplatin- and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) biological therapy, and an anti-epidermal growth factor receptor (EGFR) therapy (if expanded RAS wild-type) can next receive oral systemic therapy with either trifluridine + tipiracil or regorafenib, according to the National Comprehensive Cancer Network colon cancer guidelines.1
Regorafenib treatment should be interrupted for any National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 or 4 adverse reaction.

Seed data: Link 1, Link 3, Link 6, Link 7, Link 8
Host image: StyleGAN neural net
Content creation: GPT-3.5,

Host

Elaine Freeman

Elaine Freeman

Podcast Content
In patients with metastatic colorectal cancer who have progressed after treatment with FOLFOX or bevacizumab, the most appropriate treatment recommendation is follow-up with "A" .
Bowel cancer is the leading cause of cancer - an estimated 2.5 million people died of colon cancer in the United States in 2008, resulting in 49,960 deaths. Although colorectal cancer has been treated, there is still a high risk of metastatic cancer due to tumor growth and the area in which the cancer cells are located, as well as the potential for metastases after treatment.
Recurrent colorectal cancer can cause the cancer to spread to other parts of the body and cause complications such as colorectal cancer. Unruly, coloured cancer occurs when the cancer returns to the same part of the colon or rectum.
Various treatment options are available to patients based on the stage of colorectal cancer. Observations based on a randomized trial in patients with recurrent colorectal cancer in the United States and Canada.
The risk of relapse in the distance is reduced in patients with stage III colon cancer aged 75 and over. Observations from a randomized factor study in the USA and Canada on colorectal cancer patients.
RAS gene mutation tests extend the ability of RAS to predict survival in patients with advanced colorectal cancer in the US. A randomized trial of bevacizumab and oxaliplatin combined in patients with untreated advanced colorectal cancer that provides the best possible outcome for the treatment of patients with advanced colorectal cancer.
We hope that this improved predictive score for the benefit of chemotherapy will provide additional information in the future that can guide the treatment of patients with advanced colorectal cancer and their treatment options. The risk of late-stage colorectal cancer could be reduced by 70% in a randomized trial of bevacizumab and oxaliplatin in patients with advanced colorectal cancer.
The second stage disease had a median age of 60 years and a mortality rate of 4.5%, and the group became destitute for a total of 2.7 years, with an average age at the beginning of the study of 6.2 years.
Computed tomography is the first imaging method of choice for diagnosing suspected malignant GI in colorectal cancer patients and has already been used in a variety of other cancers, including breast, prostate and lung. The prognosis varied from excellent results associated with MSI-T3 primary to intestinal obstruction with MSS-T4 primary, with an average mortality rate of 4.5% and a mean age of 60 years.
In this case, the radiologist could be the first to diagnose colorectal cancer based on CT results. Often colorectal cancer is detected or suspected without a colonoscopy, CT or MRI, as is recommended when planning treatment. This plays a role in many patients who cannot tolerate colonoscopy, but it is often recommended with a CT, MRI or both.
Doctors recommend certain screening tests for healthy people with no signs or symptoms, such as looking for signs and symptoms of colorectal cancer and signs of colorectal cancer in healthy adults.
Doctors generally recommend that people with an average risk of colorectal cancer start screening at age 50. Diagnosing colon cancer in its early stages offers a greater chance of cure.
People with a family history of colorectal cancer have an increased risk of developing the disease. Those at average risk or at increased risk of colorectal cancer at age 50 should consider screening.
If a direct family member has been diagnosed with bowel cancer, the risk is higher in people with a family history. If individuals are more closely related, they may also share defective genes in the same gene pool.
Bowel cancer is the third most common cancer diagnosis in the United States, making it one of the more widely recognized preventable cancers. Hereditary colorectal cancers account for about a third of all colorectal cancers, but only 1.5 percent of colorectal cancer deaths.
Here we present the case of a 50-year-old man who complained of abdominal pain and weight loss over a period of 3 months. A biopsy and colonoscopy finally revealed that the patient's colorectal cancer consisted of adenocarcinoma and squamous cell carcinoma, which represents a significant increase in pathology in patients with colorectal cancer. No signs of adenosquamephaloma were found in his stool samples.
In 1974, McIntosh et al. was the first to describe a case of colon cancer that spread to the breast. It is not uncommon that primary colorectal cancer metastases into the ovaries, but very rare. This study reports the presence of adenocarcinoma and squamous cell carcinoma in the colon of a 50-year-old man, which was confirmed by a pathological examination using immunohistochemistry.
On July 8, 2015, a 47-year-old patient arrived with a breast node in her right breast, and on July 9, her breast cancer metastasized in her ovaries.